1. Yu, Xiu-Zhang, Yuan, Jia-Ling, Ye, Hui, Qie, Ming-Rong, Hou, Min-Min. 2021. TRIM44 facilitates ovarian cancer proliferation, migration, and invasion by inhibiting FRK. In Neoplasma, 68, 751-759. doi:10.4149/neo_2021_201128N1285. https://pubmed.ncbi.nlm.nih.gov/34034495/
2. Wang, Heng, Fang, Zi-Ling, Zhang, Gong-Hao, Ma, Xin. 2018. TRIM44, a crucial target of miR-410, functions as a potential oncogene in osteosarcoma. In OncoTargets and therapy, 11, 3637-3647. doi:10.2147/OTT.S163163. https://pubmed.ncbi.nlm.nih.gov/29950867/
3. Yamada, Yuta, Kimura, Naoki, Takayama, Ken-Ichi, Kume, Haruki, Inoue, Satoshi. 2020. TRIM44 promotes cell proliferation and migration by inhibiting FRK in renal cell carcinoma. In Cancer science, 111, 881-890. doi:10.1111/cas.14295. https://pubmed.ncbi.nlm.nih.gov/31883420/
4. Zhang, Shuai, Cao, Mengru, Yan, Shi, Cai, Li, Song, Yang. 2022. TRIM44 promotes BRCA1 functions in HR repair to induce Cisplatin Chemoresistance in Lung Adenocarcinoma by Deubiquitinating FLNA. In International journal of biological sciences, 18, 2962-2979. doi:10.7150/ijbs.71283. https://pubmed.ncbi.nlm.nih.gov/35541909/
5. Goshayeshi, Ladan, Afshar, Jalil, Mehrad-Majd, Hassan. 2022. Clinical Significance of TRIM44 Expression in Patients with Gastric Cancer. In Asian Pacific journal of cancer prevention : APJCP, 23, 1725-1731. doi:10.31557/APJCP.2022.23.5.1725. https://pubmed.ncbi.nlm.nih.gov/35633558/
6. Zhang, Xin, Wu, Xiusheng, Sun, Ying, Liu, Fengjun, Chen, Cheng. 2022. TRIM44 regulates tumor immunity in gastric cancer through LOXL2-dependent extracellular matrix remodeling. In Cellular oncology (Dordrecht, Netherlands), 46, 423-435. doi:10.1007/s13402-022-00759-5. https://pubmed.ncbi.nlm.nih.gov/36512309/
智鼠故事 
